Small savings schemes latest interest rates
Small savings interest rates: The Government on Wednesday, December 31, announced the interest rates for small savings schemes for the fourth quarter of financial year 2025-26 starting from January 1st, 2026 and ending on March 31st,
Benchmark indices on Wall Street fell for the fourth day in a row, to close out 2025 on a negative note and maintain the absence of a so-called “Santa rally”, which generally occurs on the final few days of the year.
The Dow Jones fell over 300 points to close at the lows of the day,
» Read more about: Dow Jones falls 300 points as Wall Street ends 2025 with fourth day of selling »
Editors: Brian Hagene, CPA, CGMA (CPAmerica), and Susan M. Grais, CPA, J.D., LL.M. (Ernst & Young LLP)
For high–income clients, especially those already maxing out 401(k) and profit–sharing contributions, the tax–deferred retirement space can feel frustratingly limited.
Ask a beginner retail investor what they think best predicts whether a fund will outperform, and the answers tend to vary.
Some point to the long-running dominance of U.S.-focused funds as evidence of geographic superiority. Others argue that technology-heavy portfolios have structural advantages that will allow them to outperform indefinitely. However,
» Read more about: 10 Best Low-Cost Index Funds to Buy in 2026 »
The massive rotation currently unfolding within ARK Invest suggests that Cathie Wood thinks 2026 will be the definitive coming-out party for the genomic revolution.
As 2025 draws to a close,
» Read more about: Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks »
As the U.S. equity market closes 2025 near record levels, attention is already shifting to what the next year may hold for the S&P 500.
With the benchmark ending 2025 at roughly 6,896 points, expectations for 2026 center on whether the rally can extend amid slowing growth, elevated valuations, and a changing monetary policy backdrop.
» Read more about: ChatGPT predicts S&P 500 index for the end of 2026 »
Get earnings reminders, our top analysis on Vanguard S&P 500 ETF, market updates, and brand-new stock recommendations delivered directly to your inbox.
Single-stock moves reflected event-driven trading. Vanda Pharmaceuticals surged after the US FDA approved its motion-sickness treatment tradipitant. Axsome Therapeutics jumped after its Alzheimer’s drug received priority review. Corcept Therapeutics plunged after regulators rejected its therapy for a form of high blood pressure. The decision widened the day’s biotech dispersion.
Silver slid as CME Group raised margins on precious-metal futures for the second time in a week.